Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Beneish M-Score: -0.64 (As of Jun. 27, 2026)


SHSE:688336 Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
76 GF Score
Price ¥41.46
GF Value ¥66.54
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Sunshine Guojian Pharmaceutical (Shanghai) Co Beneish M-Score?

Sunshine Guojian Pharmaceutical (Shanghai) Co SHSE:688336 -6.83% 76 Beneish M-Score is -0.64 as of Jun. 27, 2026. GuruFocus rates SHSE:688336 with a GF Score™ of 76/100 and a GF Value™ of ¥66.54 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks worse than 80.51% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.64 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Sunshine Guojian Pharmaceutical (Shanghai) Co's Beneish M-Score or its related term are showing as below:

SHSE:688336' s Beneish M-Score Range Over the Past 10 Years
Min: -3.74   Med: -2.14   Max: 30.91
Current: -0.64

During the past 13 years, the highest Beneish M-Score of Sunshine Guojian Pharmaceutical (Shanghai) Co was 30.91. The lowest was -3.74. And the median was -2.14.


Sunshine Guojian Pharmaceutical (Shanghai) Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sunshine Guojian Pharmaceutical (Shanghai) Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Guojian Pharmaceutical (Shanghai) Co Beneish M-Score Chart

Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.99 -3.29 -2.11 -1.94 -1.13

Sunshine Guojian Pharmaceutical (Shanghai) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.69 -1.91 -3.74 -1.13 -0.64

SHSE:688336 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Guojian Pharmaceutical (Shanghai) Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunshine Guojian Pharmaceutical (Shanghai) Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sunshine Guojian Pharmaceutical (Shanghai) Co's Beneish M-Score falls into.


SHSE:688336
76GF Score
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunshine Guojian Pharmaceutical (Shanghai) Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sunshine Guojian Pharmaceutical (Shanghai) Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5058+0.528 * 0.8066+0.404 * 0.6075+0.892 * 3.4895+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2967+4.679 * 0.020528-0.327 * 0.6289
=-0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥310 Mil.
Revenue was 431.234 + 3083.122 + 473.983 + 330.894 = ¥4,319 Mil.
Gross Profit was 348.043 + 3008.535 + 406.947 + 214.586 = ¥3,978 Mil.
Total Current Assets was ¥6,092 Mil.
Total Assets was ¥8,948 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,534 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥181 Mil.
Total Current Liabilities was ¥277 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.
Net Income was 178.118 + 2500.444 + 208.538 + 87.366 = ¥2,974 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -154.666 + 230.211 + 2625.508 + 89.721 = ¥2,791 Mil.
Total Receivables was ¥176 Mil.
Revenue was 311.119 + 254.164 + 342.785 + 329.725 = ¥1,238 Mil.
Gross Profit was 236.099 + 181.115 + 270.604 + 231.79 = ¥920 Mil.
Total Current Assets was ¥3,040 Mil.
Total Assets was ¥6,042 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,533 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥174 Mil.
Total Current Liabilities was ¥297 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(309.907 / 4319.233) / (175.589 / 1237.793)
=0.07175 / 0.141857
=0.5058

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(919.608 / 1237.793) / (3978.111 / 4319.233)
=0.742942 / 0.921023
=0.8066

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6092.103 + 1534.264) / 8948.305) / (1 - (3039.525 + 1532.969) / 6041.855)
=0.147731 / 0.243197
=0.6075

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4319.233 / 1237.793
=3.4895

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1532.969)) / (0 / (0 + 1534.264))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(180.551 / 4319.233) / (174.389 / 1237.793)
=0.041802 / 0.140887
=0.2967

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 277.049) / 8948.305) / ((0 + 297.456) / 6041.855)
=0.030961 / 0.049233
=0.6289

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2974.466 - 0 - 2790.774) / 8948.305
=0.020528

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sunshine Guojian Pharmaceutical (Shanghai) Co has a M-score of -0.64 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.64 mean?
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a Beneish M-Score of -0.64 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #669 out of 831 companies in the Biotechnology industry, placing it in the top 80.5%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's Beneish M-Score too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Beneish M-Score is -0.64. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #669 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #669 out of 831 companies for Beneish M-Score. This places Sunshine Guojian Pharmaceutical (Shanghai) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Beneish M-Score is -0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Possible Value Trap. The stock's GF Value™ is ¥66.54, compared to a current price of ¥41.46 — trading 37.7% below its estimated fair value. The current Beneish M-Score is -0.64. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current Beneish M-Score is -0.64 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued. The current stock price of ¥41.46 is trading 37.7% below its estimated GF Value™ of ¥66.54. GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Possible Value Trap.

Key valuation signals for SHSE:688336:

  • Beneish M-Score: -0.64
  • GF Value™: ¥66.54 vs. price of ¥41.46 (37.7% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Address No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
76GF Score

Get the complete analysis for SHSE:688336

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥41.46
Price
¥66.54
GF Value